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Background: To investigate the effect of computed tomography (CT) contrast enhancement (CE) on the 3D dose
distributions of non-coplanar small field beams in the CyberKnife (CK) treatment planning system (TPS) for the
stereotactic ablative radiotherapy (SABR).
Methods: Twenty-two pre-CE CT treatment plans were recruited to this retrospective plan study. Their post-CE CT
plans were based on the pre-CE CT plan data and calculated using the same MU and beam paths in either
Ray-Tracing or Monte Carlo (MC) algorithms. The differences in the doses of the beam path and the reference point
between the pre- and post-CE CT plans were compared. The minimum, maximum, and mean doses in dose-volume
histograms (DVHs) of target and organs-at-risk (OARs) were also compared.
Results: The dose differences between the pre- and post-CE plans in a single beam path were less than 1.05% in both
calculation algorithms, with respect to the prescription dose. At the center of the target volume, it was 1.9% (maximum
6.2%) in Ray-Tracing and 1.6% (maximum 4.0%) in MC. The CA effect showed on average 1.2% difference in the OAR
maximum dose (maximum 7.8% in Ray-Tracing and 7.2% in MC). In the lung cases, the CT CE resulted in a dose
difference of 2.4% (from 1.0% to 6.5%) without the calculation algorithm effect (maximum 20.3%).
Conclusions: The CK treatment plan using the post-CE CT generally afforded less than 2% dose differences from the
pre-CE CT plan. However, it could be up to 7.8% depending on the target positions in a body and be more than 20%
with the calculation algorithms. Thus, the post-CE CT in CK treatment plans should be used with careful consideration
for the CA effect, target position, and calculation algorithm factors.
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The dose distributions for modern radiotherapy have
been accurately predicted with computed tomography
(CT)-based treatment planning systems (TPS). The CT
data include the Hounsfield unit (HU) as a linear trans-
formation of the beam attenuation that varies with the
electron densities of materials on the beam path. The
TPS obtains the relative electron density from the rela-
tionship between the linear attenuation coefficients and
CT HU values to account for the heterogeneity in the
patient body. CT scanning is often undertaken with a
contrast agent (CA) that includes high-Z radio-opaque* Correspondence: sye@snu.ac.kr
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reproduction in any medium, provided the ormaterials. The tissue containing CA attenuates the CT
X-rays more than normal, resulting in a higher electron
density than the actual density. Thus the CT data taken
with CA used in TPS give rise to a higher value of monitor
unit (MU) than the CT data taken without CA. As a re-
sult, a dose higher than intended may be delivered to the
patient when daily treated without CA.
Many previous studies reported the effect of CA on the
dose calculation for the conventional Linac–based treat-
ment. In a phantom study, Ramm et al. (2001) found that
its effect was on average a 3% difference (max. 10.3%) [1].
In other phantom studies, however, it was less than 7%
(Rankine et al., 2008), 5% (Robar et al., 2002), and 2%
(Lees et al., 2005) [2-4]. The 3-dimensional conformal
radiotherapy (3D CRT)/Intensity modulated radiotherapy
(IMRT) treatment planning studies using patient CT data
with various targets (brain, head and neck, lung, prostate,. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ically acceptable [2,4-13]. A similar result (<1.5%) was
obtained in the tomotherapy planning system for head
and neck cancer [14]. Linac-based stereotactic radiosur-
gery/stereotactic body radiotherapy (SRS/SBRT) studies
also showed less than 3% difference [5,15]. In a Monte
Carlo (MC) study for 6 MV Linac beam using a 25 mm
collimator, the CA effect was less than 5% in the flatten-
ing filter beam and maximum 10.8% in flattening filter-
free (FFF) beam [3].
In contrast to the conventional Linac, CyberKnife®
(CK) Robotic Radiosurgery System (Accuray Inc., Sun-
nyvale, CA, USA) utilizes a 6 MV FFF beam with small
circular field collimators of 5 mm to 60 mm, and pro-
vides distinct characteristics. Unlike 3D conformal radi-
ation therapy and intensity modulated radiation therapy
that use the isocentric and coplanar beams fewer than
10 per plan, CK can use not only the isocentric, but
also the anisocentric and non-coplanar beams over 100
per plan so that it makes a steep dose fall-off and out-
standing conformity. In addition, the thickness of plan-
ning CT slices and the grid size of dose calculation are
less than 1.5 mm in CK, which is smaller than those
used in most conventional Linac plans. CK has two al-
gorithms for the dose calculation: Ray-Tracing and MC.
The MC algorithm has been reported to have a high ac-
curacy to calculate doses in heterogeneous materials
[16-18]. Due to the differences of the beam characteris-
tics mentioned before and the calculation algorithms,
the previous results of the CA effect on the dose calcu-
lation for the conventional Linac may not valid for CK.
Moreover the small dose difference in the stereotactic
ablative radiotherapy (SABR) using a large dose per
fraction can increase the risk of the severe normal tis-
sue complication. To our best knowledge, however, the
influence of CA on the CK treatment plans has not
been reported yet.
To investigate the effect of CA in CK, two CT data sets
(pre-contrast enhanced (CE) and post-CE CTs) were ac-
quired. The post-CE CT was used to fuse and delineate
the target and organs at risk (OARs), and the pre-CE CT
to calculate doses for treatment plan. Therefore, this study
used both CT sets to investigate the dose difference in the
CK TPS. The pre- and post-CE CTs were applied to calcu-
late the 3D dose distributions for the same plan beams
using the two calculation algorithms. The point dose for
each single beam path in the plan and the dose-volume
histogram (DVH) of the target and OARs were analyzed.Methods
Twenty-two treatment plans were retrospectively re-
cruited in this study, 6 for spine, 5 for prostate, 4 for lung,
2 for liver, 3 for abdominal lymph node, 1 for kidney and1 for pleura cancers. The institutional review board (IRB
NO. 2011-116) for this study was approved.
The pre- and post-CE CT were scanned before and
after the CA injection to the patient. The IOMERON
350 (Bracco, Milan, Italy) was used as a CA with a
concentration of 350 mg I/ml and a relative density of
1.39. The amount of CA was 140 ml for every patient.
The delay time between the CA injection and the start
of the CT scan was 70 sec. The CT scanner was
SOMATOM Sensation 64-channel (Siemens, Erlangen,
Germany). The CT scans were performed with the
same position. The time interval between pre- and
post-CE CT scans was less than two minutes. Both CT
scans were taken at the phase of suspended full expir-
ation. All patients had the CT scans at 120 kVp with
83-250 mAs.
The patients were treated with the G4 CK system and
treatment planning was made using a Multi-Plan v2.0
TPS (Accuray Inc., Sunnyvale, CA, USA). A total of 8
collimators from 10 mm to 40 mm were used, but for
each patient plan the maximum number of collimator
used was 2. On average 209 beams were used in a plan
with an average of 183 beams per collimator. The aver-
age MU per beam was 260 MU (17 MU~ 782 MU). In
the planning, the maximum MU per beam per fraction
was set to the range of 150 MU to 200 MU. The patients
were treated with pre-CE CT plans. Their post-CE CT
plans were based on the pre-CE CT plan data and cal-
culated using the same MU and beam paths in either
Ray-tracing or MC algorithms. Therefore, four plans
per patient were generated and their structure and 3D
dose distributions were exported as a DICOM file for
analysis.
A MIM software (MIM Software Inc., Cleveland, OH,
USA) was used to evaluate the amount of HU change in
OARs between the pre- and post-CE CTs. The varied
electron densities of the voxels in the CT depending on
the degree of CA absorption change the effective depths
through the beam paths affecting the computation of the
dose. The effective depths for small field beams in a plan
were calculated by the Multi-Plan TPS. The beam text
file (‘BM_patient ID_plan name.txt’) included the effect-
ive depths for each beam path. The reference point in-
formation was also acquired from the same file. The
reference point was positioned at the center of the target
volume. The differences in effective depths and doses of
the beam path and the reference point between the pre-
and post-CE CT plans were compared. The number of
beams with a dose difference more than the average dif-
ference was counted and the percentage of the beams
was calculated.
The DVHs of the target and OAR were calculated
from the DICOM files of the structures and 3D doses by
using the MIM software. The minimum, maximum, and









Aorta 5 53 223 171 ± 40
Heart 5 12 164 155 ± 7
Kidney 10 13 158 124 ± 33
Lung 14 −650 121 45 ± 32
Liver 12 40 64 45 ± 14
Stomach 3 −64 55 40 ± 16
Rectum 6 17 37 33 ± 5
Urethra 5 37 42 32 ± 9
Esophagus 14 −126 67 31 ± 14
PTV 22 −16 113 30 ± 28
Bowel 17 −72 40 27 ± 9





17 41 12 6 ± 3
Femur
head
5 234 4 2 ± 1
Table 3 Dose difference of single beam paths between
pre- and post-CE





1 SD 0.03% 0.09%
Table 4 Reference point dose difference between







In RT In MC
1 Lung (Left Lower Lobe) 11.4 mm 6.2% 3.8%
2 Lt. Pleura 11.0 mm 5.7% 4.0%
3 Lung (Left Upper Lobe) 7.4 mm 3.3% 2.4%
4 T4 6.4 mm 2.7% 3.8%
5 Liver (Segment 6) 4.7 mm 2.7% 3.0%
6 PAN* 5.2 mm 2.4% 0.2%
7 Lung (Left Upper Lobe) 4.1 mm 2.1% 1.7%
8 L2 3.9 mm 2.1% 1.9%
9 SMA LN† 3.7 mm 1.9% 1.7%
10 Liver (Segment 8) 3.2 mm 1.6% 1.1%
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ference (%) was defined as follows:
Relative dose difference %½ 
¼ Dose cGy½  with PreCE CT
 
– Dose cGy½  with PostCE CT
  
Prescription Dose cGy½  :
The dose differences between the pre- and post-CE
CT plans were tested with paired t-test. The dose differ-
ences between Ray-tracing and MC were also calculated.11 T1-2‡ 3.1 mm 1.5% 1.0%
12 L2-5§ 3.6 mm 1.3% 2.1%
13 Lung (Right Middle Lobe) 2.6 mm 1.2% 1.3%
14 Iliac LN 2.0 mm 1.1% 0.6%
15 Lt. Kidney (Renal Pelvis) 4.4 mm 1.0% 1.2%
16 Prostate 1.2 mm 0.8% 1.1%
17 C5|| 1.5 mm 0.7% 1.1%
18 C5-T2 3.1 mm 0.6% 0.5%
19 Prostate 1.2 mm 0.6% 0.7%Results
HU changes due to the CA injection
The degree of HU change for OARs due to the CA in-
jection in CT scans is shown in Table 1. The baselines of
HU were the average HU values of OARs in pre-CE
CTs. The aorta showed the largest change in HU,
followed by the heart and kidney. These 3 CA-sensitive
OARs showed an average difference of over 124 HU
(maximum 223).Table 2 Difference of effective depth between pre- and
post-CE
Effective depth difference |(pre-CE) – (post-CE)|
Max 68.1 mm
Average 4.0 mm
1 SD 5.1 mmEffect of contrast enhancement (CE) on the effective
depth, target volume and dose of a single beam path
With the CA, the effective depths increased, resulting in
decreased doses. Table 2 shows that the change in the
effective depth was 4.0 mm on average, with a maximum
of 68.1 mm. We analyzed the correlation between the
target volumes and the dosimetric differences and found20 Prostate 1.6 mm 0.6% 1.1%
21 Prostate 1.1 mm 0.5% 0.4%
22 Prostate 1.1 mm 0.4% 0.9%
Average ± 1SD 4.0 ± 2.9 mm 1.9 ± 1.6% 1.6 ± 1.1%
*PAN : Paraaortic lymph node.
†SMA LN : Superior mesenteric artery lymph node.
‡T : Thoracic spine.
§L : Lumbar spine.
||C : Cervical spine.
Figure 1 DVH of target in case 8 (L-spine (L2) plan), as an example to show the CA effect on the target in most of the cases.
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dose maximum (P-value = 0.08 and 0.07 in Ray-tracing and
MC), mean dose (P-value = 0.09 and 0.08 in Ray-tracing
and MC), and dose minimum (P-value = 0.11 and 0.33 in
Ray-tracing and MC). As shown in Table 3, the dose dif-
ferences between the pre- and post-CE plans in a single
beam path were insignificant (in average, 0.01 ± 0.03% and
0.05 ± 0.09% of the prescription dose for the Ray-tracing
and MC algorithms, respectively). But it was nevertheless
statistically significant (P-value < 0.001).
Effect of contrast enhancement (CE) on doses and DVH of
target and OAR
Table 4 shows lower doses with same MU at the reference
point due to the existence of CA in both algorithms. Due
to the CE, the dose difference at the center of theFigure 2 DVH of target in case 2 (pleura plan) that shows the largest
post-CE CTs).target volume (i.e., the reference point) was 1.9% ±
1.6% (maximum 6.2%) in Ray-tracing and 1.6% ± 1.1%
(maximum 4.0%) in MC; this difference was statisti-
cally significant (P-value < 0.001). It was maximum 409
cGy under the prescription dose of 6600 cGy. The
highest dose difference occurred in cases 1 and 2, the
plan for lung (6.2% in Ray-tracing) and pleura (4.0% in MC).
For the pelvis region (cases 14, 16, and 19-22), the average
dose difference at the reference point was 0.7% in Ray-
tracing and 0.8% in MC. For other regions, it was 2.3%
and 1.9% in Ray-tracing and MC, respectively.
When the mean difference of effective depths had a
difference over 10 mm, the dose difference at the target
center (e.g., the reference point) was 4.9% on average
considering both algorithms together. However, it was
1.1% when the mean deff difference was less than 4 mm.difference in the target dose between the two CTs (pre- and
Figure 3 DVH of target in case 1 (lung (LLL) plan) that is a specific case to show the large dose difference due to the combined effect
of the contrast enhancement (CE) and different calculation algorithms.
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8 that represents the CA effect on the target in most
cases. The target volume receiving the prescription dose
was changed by 2% in Ray-tracing and 3.4% in MC. The
largest difference in the target between the two CTs (p- and
post-CE CTs) occurred in case 2 (pleura plan) (Figure 2).
As a specific case, the target DVH for case 1 [lung (LLL)
plan] in Figure 3 showed a large dose difference especially
in Ray-tracing due to the combined effect of CE and algo-
rithm limitation. Table 5 shows that the differences in the
minimum, maximum and mean doses to the target were
1.0% to 1.9% on average, and were statistically significant
(P-value <0.05).
In Table 6, the minimum and mean doses differences
of the OAR were less than 0.3% on average. The max-
imum dose of contrast-enhanced OAR was decreased by
0.8% ± 1.1% (P-value < 0.001) in Ray-tracing and 0.9% ±
1.2% (P-value < 0.001) in MC. The maximum OAR dose
difference in Tables 6 and 7 was found in case 1. The max-
imum difference in the mean dose was shown in case 2.
For this case, Figure 4 shows the dose distributions de-
pending on the CA existence and the different calculation
algorithms.
Table 7 lists the maximum and mean values of the
maximum-dose difference due to the CE on OARs. Among
the OARs, the lung had the largest differences in the maxi-Table 5 Target dose difference between pre- and post-CE
In RT In MC
Dmin Dmax Dmean Dmin Dmax Dmean
Max 5.3% 7.8% 6.8% 3.2% 4.5% 3.4%
Average 1.3% 1.9% 1.7% 1.0% 1.6% 1.2%
1 SD 1.3% 1.8% 1.6% 0.8% 1.1% 0.7%
p-value 0.011 0.005 0.002 0.012 <0.001 <0.001mum dose (7.8% in Ray-tracing). In MC, the highest differ-
ence in the mean value occurred in aorta (2.8%), followed
by heart (1.5%), liver (1.4%), lung (1.3%), and kidney
(0.8%). The maximum difference of maximum dose of
these OARs was over 2.4%. Figures 5 and 6 show the
DVHs of aorta and cauda equina, as examples of the
largest maximum-dose difference and the normal-dose
difference.
Dose differences due to different calculation algorithms
The doses calculated with the two different algorithms
(Ray-tracing and MC) were compared. For small field
beams, the dose difference between the two calculation
algorithms was on average 0.1% (maximum 2% or 100
cGy) per beam, but it was statistically significant
(P-value < 0.001). The reference point dose difference
(average 2.6%) between the two algorithms was not
statistically significant. However, it was maximum 8.7%,
depending on the position of target.
The difference in the target doses between the two al-
gorithms was on average 3.5% ± 4.1% (maximum 20.3%)
(P-value = 0.013). However, for the OARs, the mean dose
difference was statistically significant (average 4.3% ±
2.6%, maximum 13.3%). In low doses (less than 10% of
the prescription dose), a large dose difference between
the algorithms is shown in Figure 5.Table 6 OAR dose difference between pre- and post-CE
In RT In MC
Dmin Dmax Dmean Dmin Dmax Dmean
Max 2.7% 7.8% 1.4% 1.3% 7.2% 2.1%
Average 0.1% 0.8% 0.2% 0.1% 0.9% 0.2%
1 SD 0.2% 1.1% 0.2% 0.2% 1.2% 0.4%
p-value 0.727 <0.001 <0.001 0.029 <0.001 <0.001
Table 7 Maximum/Mean values of maximum-dose
difference in each OAR
OARs Maximum of Dmax Average of Dmax
In RT In MC In RT In MC
Aorta 3.8% 4.5% 2.0% 2.8%
Heart 3.5% 3.3% 1.3% 1.5%
Lung 7.8% 5.9% 1.5% 1.3%
Liver 2.9% 7.2% 0.6% 1.4%
Kidney 2.4% 2.7% 0.7% 0.8%
Bowel 1.7% 2.5% 0.7% 0.8%
Spinal cord/Cauda equina 2.0% 1.8% 0.7% 0.7%
Urethra 0.6% 1.1% 0.4% 0.6%
Rectum 0.7% 1.2% 0.5% 0.5%
Esophagus 2.0% 1.6% 0.7% 0.5%
Stomach 0.2% 0.9% 0.1% 0.4%
Bladder 0.8% 0.7% 0.4% 0.3%
Femur head 0.3% 0.6% 0.1% 0.2%
Figure 4 Dose distribution in case 2 having a maximum difference in
different calculation algorithms.
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The dose at the center of the target had a difference of
1.9% in Ray-tracing and 1.6% in MC because the CK
treatment plans normally used over 200 beams, although
the dose difference due to CA was small (on average
0.1% or less for the prescription dose) for each single
beam path with small field size in a plan. In CK treat-
ment planning, the dose difference between MC and
Ray-tracing due to the CA is resulted from the various
planning parameters including the MU (0-150 MU in
this study) of single beam path, the distance between the
central axis of beam and the reference point, the collima-
tor size, the number of beams passing the CA-uptaken
structure, and the calculation accuracy of scattered
dose.
The study from Amato, et al. showed that the relative
increase of HU due to CA was 74% (from 121.7 to 161.9
HU) for kidney, 48% (from 95.8 to 105.8 HU) for thy-
roid, 22% (from 55.3 to 62.2 HU) for liver, and so on
[19]. In addition, in this study, the HU and dose to the
aorta were affected most significantly by CE, followed in
order by the heart, liver, lung, and kidney. Those OARs
sensitive to CE had a difference of 2.8% in the average ofmean dose to the target, depending on the CA existence and the
Figure 5 DVH of aorta in case 2 (pleura plan).
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pleura, lung and thoracic spine plans passed through the
aorta, lung and heart, those plans had an increased dif-
ference in the mean dose to the target, which was 5.1%
and 3.4% in the pleura plan, 3.3% and 1.3% in the lung
plan and 2.6% and 2.1% in the thoracic spine plan with
Ray-tracing and MC, respectively. The maximum dose
in the lung, aorta, heart and spinal cord was also re-
duced by up to 7.8% due to the CE. From these observa-
tions, for a target close to OARs that increased the CA
absorption, the CK treatment plan using the post-CE CT
could deliver a higher dose to the OAR as well as to the
target. This result can lead to the severe OAR complica-
tion considering a large dose per fraction of SABR. Un-
like the other commercial TPS for Linac, the Multi-Plan
v2.0 TPS of CK cannot override the density for the
structures. The fine-tuning of MU per single beam path
in a plan can modify the dose distribution but the re-Figure 6 DVH of cauda equina in case 12 (L-spine (L2 to L5) plan).optimization only can arrange the beam paths to control
the entrance of beams into the CA-uptaken structures.
Therefore, the post-CE CT should be carefully used in
CK treatment planning if a target is positioned where
many beams pass through the aorta or lung, because a
dose difference can occur due to the CE. On the other
hand, when the target is in the pelvis region (e.g., pros-
tate, iliac lymph node, and lumbar spine) or only a few
beams pass the aorta or lung, use of the post-CE CT in
CK planning is clinically acceptable (≤1%).
For the dose calculation, the Ray-tracing algorithm
uses the commissioned beam data measured in water
and the effective depth and the MC uses the electron
transport algorithm calculating the absorbed dose to
various materials that can provide the higher accuracy
on the target dose calculation in a patient than the Ray-
tracing algorithm. The dose distribution for the lung
plan differed by up to 28% depending on the calculation
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maximum dose difference for the lung plan was 20.3% in
the target and 13.3% in the OARs. According to this
study and previous literatures [16-18,20], recommended
is the use of MC algorithm to calculate the target dose
for the SABR CK planning in lung cancer treatment or
in other lesions using the large number of beams passing
through the lung. It is noted that the MC algorithm re-
sults in the large statistical uncertainty for the low dose
region. In addition, the CT CE in the lung cases resulted
in a dose difference of 2.4% (from 1.0% to 6.5%) without
this calculation algorithm effect. Thus, the use of both
the post-CE CT and Ray-tracing algorithm can lead to
an incorrect dose calculation and an inappropriate CK
plan for lung cancer patient treatment.
Conclusions
The CK treatment plan showed a mean dose difference
of less than 2% in both the target and OARs due to the
CT CE, although the CK utilizes the small field collima-
tors, FFF beams, and multiple non-coplanar beams more
than 200. However it could be up to 7.8% to the target
and OARs, depending on the target position in a body.
In addition to the use of CA, the dose difference can make
a large difference of up to 20% with calculation–algorithm
effect combined. The large dose difference can lead to the
severe complication to OAR in SABR considering a high
dose per fraction. In conclusion, the post-CE CT in CK
treatment planning should be used with careful con-
sideration for these factors when the target is close to
CA-sensitive OARs.
Abbreviations
CT: Computed tomography; TPS: Treatment planning systems; OAR: Organs-at-risk;
HU: Hounsfield unit; CA: Contrast agent; MU: Monitor unit; 3D CRT: 3-dimensional
conformal radiotherapy; IMRT: Intensity modulated radiotherapy; SRS: Stereotactic
radiosurgery; SBRT: Stereotactic body radiotherapy; MC: Monte Carlo;
FFF: Flattening filter-free; CK: CyberKnife; SABR: Stereotactic ablative
radiotherapy; CE: Contrast enhanced; DVH: Dose-volume histogram.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
HJK designed the study, acquired and interpreted the data, and wrote the
manuscript. ARJ contributed to the interpretation of the data and involved in
drafting the manuscript. YKP participated to data analysis. SJY contributed to
the overall experimental design and involved in revising the manuscript
critically. All authors have given final approval of the version to be published.
Author details
1Department of Radiation Oncology, Soonchunhyang University Hospital,
Seoul, South Korea. 2Department of Biomedical Engineering and Institute of
Radiation Medicine, Seoul National University, Seoul, South Korea.
3Department of Radiation Oncology, Seoul National University Hospital,
Seoul, South Korea. 4Department of Transdisciplinary Studies and Advanced
Institutes of Convergence Technology, Seoul National University, Suwon,
South Korea.
Received: 5 February 2013 Accepted: 22 September 2013
Published: 18 October 2013References
1. Ramm U, Damrau M, Mose S, Manegold KH, Rahl CG, Bottcher HD:
Influence of CT contrast agents on dose calculations in a 3D treatment
planning system. Phys Med Biol 2001, 46:2631–2635.
2. Rankine AW, Lanzon PJ, Spry NA: Effect of contrast media on megavoltage
photon beam dosimetry. Med Dosim 2008, 33:169–174.
3. Robar JL, Riccio SA, Martin MA: Tumour dose enhancement using
modified megavoltage photon beams and contrast media. Phys Med Biol
2002, 47:2433–2449.
4. Lees J, Holloway L, Fuller M, Forstner D: Effect of intravenous contrast on
treatment planning system dose calculations in the lung. Australas Phys
Eng Sci Med 2005, 28:190–195.
5. Xiao J, Zhang H, Gong Y, Fu Y, Tang B, Wang S, Jiang Q, Li P: Feasibility of
using intravenous contrast-enhanced computed tomography (CT) scans
in lung cancer treatment planning. Radiother Oncol 2010, 96:73–77.
6. Weber DC, Rouzaud M, Miralbell R: Bladder opacification does not
significantly influence dose distribution in conformal radiotherapy of
prostate cancer. Radiother Oncol 2001, 59:95–97.
7. Shibamoto Y, Naruse A, Fukuma H, Ayakawa S, Sugie C, Tomita N: Influence
of contrast materials on dose calculation in radiotherapy planning using
computed tomography for tumors at various anatomical regions: a
prospective study. Radiother Oncol 2007, 84:52–55.
8. Shi W, Liu C, Lu B, Yeung A, Newlin HE, Amdur RJ, Olivier KR: The effect of
intravenous contrast on photon radiation therapy dose calculations for
lung cancer. Am J Clin Oncol 2010, 33:153–156.
9. Liauw SL, Amdur RJ, Mendenhall WM, Palta J, Kim S: The effect of
intravenous contrast on intensity-modulated radiation therapy dose
calculations for head and neck cancer. Am J Clin Oncol 2005, 28:456–459.
10. Elawadi A-S, Bayoumi Y, Alomran R, El-Moniem RA, Ismail A, Alamro A: Does
intravenous contrast agent affect dose calculations of three dimensional
treatment planning system? Bull Alex Fac Med 2009, 45:103–108.
11. Choi Y, Kim JK, Lee HS, Hur WJ, Hong YS, Park S, Ahn K, Cho H: Influence of
intravenous contrast agent on dose calculations of intensity modulated
radiation therapy plans for head and neck cancer. Radiother Oncol 2006,
81:158–162.
12. Burridge NA, Rowbottom CG, Burt PA: Effect of contrast enhanced CT
scans on heterogeneity corrected dose computations in the lung. J Appl
Clin Med Phys 2006, 7:1–12.
13. Xiong W, Huang D, Gewanter R, Burman C: SU-E-T-545: dose comparison
between intravenous contrast-enhanced CT and non contrast CT in
treatment planning. In AAPM. ; 2012:3831.
14. Xu Y, Watchman C, Krafft S, Jang S: SU-GG-T-607: effect of CT contrast
materials on dose calculations in tomotherapy planning system. In AAPM;
2010:3327.
15. Zabel-du Bois A, Ackermann B, Hauswald H, Schramm O, Sroka-Perez G,
Huber P, Debus J, Milker-Zabel S: Influence of intravenous contrast agent
on dose calculation in 3-D treatment planning for radiosurgery of
cerebral arteriovenous malformations. Strahlenther Onkol 2009,
185:318–324.
16. Ma CM, Li JS, Deng J, Fan J: Implementation of Monte Carlo Dose
calculation for CyberKnife treatment planning. J Phys 2008, 102:012016.
17. Wilcox EE, Daskalov GM: Accuracy of dose measurements and
calculations within and beyond heterogeneous tissues for 6 MV photon
fields smaller than 4 cm produced by Cyberknife. Med Phys 2008,
35:2259.
18. Ma C, Li J, Deng J, Fan J: WE-C-AUD-03: Investigation of Fast Monte Carlo
Dose Calculation for CyberKnife SRS/SRT Treatment Planning. Med Phys
2007, 34:2589–2590.
19. Amato E, Lizio D, Settineri N, Di Pasquale A, Salamone I, Pandolfo I: A
method to evaluate the dose increase in CT with iodinated contrast
medium. Med Phys 2010, 37:4249–4256.
20. Sharma SC, Ott JT, Williams JB, Dickow D: Clinical implications of adopting
Monte Carlo treatment planning for CyberKnife. J Appl Clin Med Phys
2010, 11:3142.
doi:10.1186/1748-717X-8-244
Cite this article as: Kim et al.: Dosimetric effect of CT contrast agent in
CyberKnife treatment plans. Radiation Oncology 2013 8:244.
